Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01904721 | A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) | PHASE2 | COMPLETED | 244 | — | — | Aug 1, 2013 | Jan 1, 2015 | Mar 22, 2016 | 1 | United States |
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm\^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs) and a negative change from Baseline indicated worsening (decrease in the number of terminal hairs).
The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: "Since the start of the study, the amount of my hair has?": Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.
| Arm | Type | Description |
|---|---|---|
| Stage 1: Bimatoprost Solution 1 Twice Daily | EXPERIMENTAL | Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days. |
| Stage 1: Bimatoprost Solution 1 Once Daily | EXPERIMENTAL | Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days. |
| Stage 1: Bimatoprost Solution 2 Twice Daily | EXPERIMENTAL | Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days. |
| Stage 1: Bimatoprost Solution 2 Once Daily | EXPERIMENTAL | Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days. |
| Stage 2: Bimatoprost Solution 1 Twice Daily | EXPERIMENTAL | Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months. |
| Stage 2: Bimatoprost Solution 2 Twice Daily | EXPERIMENTAL | Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months. |
| Stage 2: Bimatoprost Vehicle Twice Daily | PLACEBO_COMPARATOR | Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months. |
| Name | Type | Description |
|---|---|---|
| Bimatoprost Solution 1 | DRUG | Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months. |
| Bimatoprost Solution 2 | DRUG | Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months. |
| Bimatoprost Vehicle | DRUG | Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months. |
Inclusion Criteria: * Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year * Willingness to maintain same hair style, length and hair color during study * Willingness to have micro-dot-tattoo applied to scalp (Stage 2 only) Exclusion Criteria: * ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | Ritlecitinib, Ritlecitinib higher dose, LITFULO, Litfulo |
| Veradermics, Incorporated | MANE | 4 | PHASE3 | VDPHL01 |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Upadacitinib |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Baricitinib, LY4005130 |
| ICON Plc | ICLR | 1 | PHASE3 | Clascoterone 5%, Vehicle |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE2 | Amlitelimab |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | bempikibart |
| Absci Corporation | ABSI | 1 | PHASE1 | ABS-201 Single Dose, ABS-201 Multiple Doses |
| Forte Biosciences Inc. | FBRX | 1 | PHASE1 | FB102 |
| HCW Biologics, Inc. | HCWB | 1 | PHASE1 | HCW9302, an IL-2 fusion protein |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | Dupilumab |